相关实验视频

Updated: Jan 18, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

用一种生物灵感的连接体准B类掠食受体1型,诱导AML中的亡或亡

Adam Y Lin^1,2, Jonathan S Rink^1,2,3, Eva Yang¹

¹Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.

Blood neoplasia

|September 11, 2025

概括

新的高密度脂蛋白纳米颗粒向吸尘器受体类B型1 (SR-B1) 显示出治疗急性髓性白血病 (AML) 的前景. 这些纳米粒子有效地杀死AML细胞,并与现有疗法协同作用.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 的预后仍然很差,特别是在老年人和那些有不良风险因素的人群中.
拾取者受体类B类型1 (SR-B1),参与胆固醇稳态,在AML细胞中表达,并与不良结果相关.
准SR-B1为AML提供了一个潜在的新治疗策略.

研究的目的:

评估一种合成生物启发的高密度脂蛋白纳米粒子 (HDL NP) 接体的疗效,该接体针对AML中的SR-B1.
研究HDL NP作用的机制,包括对细胞死亡途径和分化的影响.
评估HDLNP与标准AML治疗的协同作用潜力.

主要方法:

在低纳米分子度下治疗AML细胞与HDLNP.
评估HDL NP对谷氨过氧化酶4的影响,反应性氧物种的积累和细胞死亡 (ferroptosis,apoptosis,pyroptosis).
评估HDLNP与cytarabine,venetoclax和gilteritinib的协同作用;评估AML细胞分化.

主要成果:

在AML模型中,HDL NPs表现出与cytarabine相比更高的疗效.
HDL NP治疗降低了谷氨过氧化酶4,诱导了活性氧物种,并触发了混合细胞死亡途径.
高密度LNP与标准AML疗法产生协同效应,并诱导AML细胞分化.

结论:

针对SR-B1的HDLNP代表了AML的一种强有力的治疗方法.
该机制涉及破坏胆固醇代谢,氧化还原平衡和诱导多种细胞死亡模式.
治疗HDL NP是一种有希望的策略,有可能克服耐药性并改善AML的结果.

更多相关视频

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

相关概念视频

Phagocytosis of Apoptotic Cells

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or immature dendritic cells. Non-professional phagocytes such as epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes.
Normal cells contain receptors that prevent them from being recognized...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Extrinsic Apoptotic Pathway

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...